Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.
(2015) In Molecular Therapy 23(2). p.321-329- Abstract
- Oncolytic immunotherapy with cytokine armed replication competent viruses is an emerging approach in cancer treatment. In a recent randomized trial an increase in response rate was seen but the effect on overall survival is not known with any virus. To facilitate randomized trials, we performed a case-control study assessing the survival of 270 patients treated in an Advanced Therapy Access Program (ATAP), in comparison to matched concurrent controls from the same hospital. The overall survival of all virus treated patients was not increased over controls. However, when analysis was restricted to GMCSF-sensitive tumor types treated with GMSCF-coding viruses, a significant improvement in median survival was present (From 170 to 208 days, P... (More)
- Oncolytic immunotherapy with cytokine armed replication competent viruses is an emerging approach in cancer treatment. In a recent randomized trial an increase in response rate was seen but the effect on overall survival is not known with any virus. To facilitate randomized trials, we performed a case-control study assessing the survival of 270 patients treated in an Advanced Therapy Access Program (ATAP), in comparison to matched concurrent controls from the same hospital. The overall survival of all virus treated patients was not increased over controls. However, when analysis was restricted to GMCSF-sensitive tumor types treated with GMSCF-coding viruses, a significant improvement in median survival was present (From 170 to 208 days, P = 0.0012, N=148). An even larger difference was seen when analysis was restricted to good performance score patients (193 versus 292 days, P = 0.034, N=90). The survival of ovarian cancer patients was especially promising as median survival nearly quadrupled (P = 0.0003, N=37). These preliminary data lend support to initiation of randomized clinical trials with GMCSF-coding oncolytic adenoviruses.Molecular Therapy (2014); doi:10.1038/mt.2014.218. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4817098
- author
- Kanerva, Anna ; Koski, Anniina ; Liikanen, Ilkka ; Oksanen, Minna ; Joensuu, Timo ; Hemminki, Otto ; Palmgren, Juni ; Hemminki, Kari LU and Hemminki, Akseli
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Molecular Therapy
- volume
- 23
- issue
- 2
- pages
- 321 - 329
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:25381801
- wos:000348750700013
- scopus:84922262706
- pmid:25381801
- ISSN
- 1525-0024
- DOI
- 10.1038/mt.2014.218
- language
- English
- LU publication?
- yes
- id
- dae7a98f-14c7-4f9e-b647-c77f723fe40c (old id 4817098)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25381801?dopt=Abstract
- date added to LUP
- 2016-04-01 09:56:43
- date last changed
- 2022-04-27 17:01:04
@article{dae7a98f-14c7-4f9e-b647-c77f723fe40c,
abstract = {{Oncolytic immunotherapy with cytokine armed replication competent viruses is an emerging approach in cancer treatment. In a recent randomized trial an increase in response rate was seen but the effect on overall survival is not known with any virus. To facilitate randomized trials, we performed a case-control study assessing the survival of 270 patients treated in an Advanced Therapy Access Program (ATAP), in comparison to matched concurrent controls from the same hospital. The overall survival of all virus treated patients was not increased over controls. However, when analysis was restricted to GMCSF-sensitive tumor types treated with GMSCF-coding viruses, a significant improvement in median survival was present (From 170 to 208 days, P = 0.0012, N=148). An even larger difference was seen when analysis was restricted to good performance score patients (193 versus 292 days, P = 0.034, N=90). The survival of ovarian cancer patients was especially promising as median survival nearly quadrupled (P = 0.0003, N=37). These preliminary data lend support to initiation of randomized clinical trials with GMCSF-coding oncolytic adenoviruses.Molecular Therapy (2014); doi:10.1038/mt.2014.218.}},
author = {{Kanerva, Anna and Koski, Anniina and Liikanen, Ilkka and Oksanen, Minna and Joensuu, Timo and Hemminki, Otto and Palmgren, Juni and Hemminki, Kari and Hemminki, Akseli}},
issn = {{1525-0024}},
language = {{eng}},
number = {{2}},
pages = {{321--329}},
publisher = {{Nature Publishing Group}},
series = {{Molecular Therapy}},
title = {{Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.}},
url = {{http://dx.doi.org/10.1038/mt.2014.218}},
doi = {{10.1038/mt.2014.218}},
volume = {{23}},
year = {{2015}},
}